Dr. Fleischman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 The City Dr S
Orange, CA 92868Phone+1 949-999-2400
Education & Training
- Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2007 - 2011
- Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 2005 - 2007
- Stanford University School of MedicineClass of 2005
Certifications & Licensure
- OR State Medical License 2013 - Present
- CA State Medical License 2013 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Start of enrollment: 2014 Jul 08
- A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis Start of enrollment: 2018 Jan 26
- The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase Start of enrollment: 2018 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Increased AID results in mutations at the CRLF2 locus implicated in Latin American ALL health disparities.Valeria Rangel, Jason N Sterrenberg, Aya Garawi, Vyanka Mezcord, Melissa L Folkerts
Nature Communications. 2024-07-27 - 1 citationsHyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemia.Benjamin J Lee, Shawn P Griffin, Jean Doh, Alexandre Chan, Stefan O Ciurea
European Journal of Haematology. 2024-03-01 - 1 citationsCharacterizing the microbiome of patients with myeloproliferative neoplasms during a Mediterranean diet intervention.Julio Avelar-Barragan, Laura F Mendez Luque, Jenny Nguyen, Hellen Nguyen, Andrew O Odegaard
Mbio. 2023-12-19
Journal Articles
- Inhibition of Interleukin-1 Receptor-Associated Kinase 1 (IRAK1) as a Therapeutic StrategyAngela Fleischman, John O. Mascarenhas, Jack W. Singer, Oncotarget
Abstracts/Posters
- JAK2V617F Hematopoietic Stem and Progenitors Are More Resistant to Chronic Blockage of IL-10 Signaling in a Murine Model of Myeloproliferative NeoplasmsAngela G. Fleischman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center DatabaseAngela G. Fleischman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Myeloproliferative Neoplasms Roundtable: How Will We Cure Myelofibrosis?60th American Society of Hematology Annual Meeting - 12/3/2018
- N-Acetylcysteine As a Therapeutic for JAK2V617F Myeloproliferative Neoplasms2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- The Importance of Developing Open Communication and a Professional, Long-Term Relationship Between Patients with Chronic Myeloid Leukemia and Their OncologistMay 23rd, 2023
- CURE Media Group Announces the 2018 MPN Heroes®November 30th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: